ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancerDavid Planchard, Dariusz M. Kowalski, Diego Márquez-Medina et al.|Annals of Oncology|2020Cited by 164
ARCTIC: Durvalumab + tremelimumab and durvalumab monotherapy vs SoC in ≥ 3L advanced NSCLC treatmentDariusz M. Kowalski, David Planchard, Niels Reinmuth et al.|Annals of Oncology|2018Cited by 17
Multicenter, placebo‐controlled, double‐blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy‐induced nausea and vomiting in patients receiving highly emetogenic chemotherapyShunichi Sugawara, Tomohide Tamura, Naoki Inui et al.|Cancer|2019Cited by 16